維拉克塔治療公司(納斯達克：VIRX-GET評級)和ESSA Pharma(納斯達克：EPIX-GET評級)都是小盤醫療公司，但哪一項是更好的投資？我們將根據這兩家公司的收益、風險、股息、分析師建議、盈利能力、機構所有權和估值等方面的實力進行比較。
熱門資訊> 正文
正面評論：維拉克塔治療公司(納斯達克代碼：VIRX)和ESSA製藥公司(納斯達克代碼：EPIX)
2022-07-06 14:21
Viracta Therapeutics (NASDAQ:VIRX – Get Rating) and ESSA Pharma (NASDAQ:EPIX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation.
Valuation and Earnings
估值和收益
Get
到達
Viracta Therapeutics
維拉克塔治療公司
alerts:
警報：
This table compares Viracta Therapeutics and ESSA Pharma's top-line revenue, earnings per share (EPS) and valuation.
此表比較了Viracta Treeutics和ESSA Pharma的營收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Viracta Therapeutics | $2.07 million | 68.46 | -$114.76 million | ($1.24) | -3.05 |
| ESSA Pharma | N/A | N/A | -$36.81 million | ($0.87) | -3.11 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 維拉克塔治療公司 | 207萬美元 | 68.46 | -1.1476億美元 | ($1.24) | -3.05 |
| Essa Pharma | 不適用 | 不適用 | -3,681萬元 | ($0.87) | -3.11 |
ESSA Pharma has lower revenue, but higher earnings than Viracta Therapeutics. ESSA Pharma is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Essa Pharma的收入低於Viracta治療公司，但收益高於Viracta治療公司。Essa Pharma的市盈率低於Viracta治療公司，這表明它目前是兩隻股票中更負擔得起的一隻。
Analyst Recommendations
分析師建議
This is a breakdown of current ratings and target prices for Viracta Therapeutics and ESSA Pharma, as reported by MarketBeat.com.
據MarketBeat.com報道，這是Viracta治療公司和ESSA Pharma的當前評級和目標價格的細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Viracta Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| ESSA Pharma | 0 | 0 | 1 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 維拉克塔治療公司 | 0 | 0 | 3 | 0 | 3.00 |
| Essa Pharma | 0 | 0 | 1 | 0 | 3.00 |
Viracta Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 455.56%. ESSA Pharma has a consensus target price of $21.00, indicating a potential upside of 674.91%. Given ESSA Pharma's higher possible upside, analysts clearly believe ESSA Pharma is more favorable than Viracta Therapeutics.
維拉克塔治療公司目前的共識目標價為21美元，這表明潛在的上漲幅度為455.56%。Essa Pharma的共識目標價為21美元，表明潛在上行空間為674.91%。考慮到ESSA Pharma更有可能的上行空間，分析師們顯然認為ESSA Pharma比Viracta治療公司更有利。
Volatility & Risk
波動性與風險
Viracta Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500.
Viracta Treateutics的貝塔指數為1.76，這意味着其股價的波動性比標準普爾500指數高76%。相比之下，ESSA Pharma的貝塔係數為1.71，這意味着其股價的波動性比標準普爾500指數高出71%。
Profitability
盈利能力
This table compares Viracta Therapeutics and ESSA Pharma's net margins, return on equity and return on assets.
此表比較了Viracta Treeutics和ESSA Pharma的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Viracta Therapeutics | N/A | -48.60% | -40.76% |
| ESSA Pharma | N/A | -19.59% | -19.19% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 維拉克塔治療公司 | 不適用 | -48.60% | -40.76% |
| Essa Pharma | 不適用 | -19.59% | -19.19% |
Institutional and Insider Ownership
機構和內部人持股
56.3% of Viracta Therapeutics shares are held by institutional investors. 27.6% of Viracta Therapeutics shares are held by insiders. Comparatively, 9.9% of ESSA Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Viracta治療公司56.3%的股份由機構投資者持有。維拉克塔治療公司27.6%的股份由內部人士持有。相比之下，ESSA Pharma 9.9%的股份由內部人士持有。強大的機構持股表明，對衝基金、捐贈基金和大型基金經理相信，從長期來看，一隻股票的表現將好於大盤。
Summary
摘要
Viracta Therapeutics beats ESSA Pharma on 6 of the 11 factors compared between the two stocks.
在兩隻股票之間的11個因素中，Viracta Treeutics在6個因素上擊敗了ESSA Pharma。
Viracta Therapeutics Company Profile (Get Rating)
維拉克塔治療公司簡介(獲取評級)
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Viracta Treateutics，Inc.是一家精確腫瘤學公司，致力於開發治療病毒相關惡性腫瘤的藥物。它的主要候選產品包括NANA-Val，與Nanatinostat和valganciclovir聯合用於EB病毒陽性淋巴瘤的第二階段臨牀試驗；用於治療各種復發/難治性EB病毒陽性(EBV+)淋巴瘤的開放標籤第二階段籃子試驗，以及用於治療EBV陽性復發或轉移性鼻咽癌和其他EBV+實體腫瘤的開放標籤1b/2試驗。該公司的開發流程包括臨牀階段的非共價ITK/BTK抑制劑維拉布替尼和臨牀前階段的PDK-1抑制劑VRX-510(以前的SNS-510)。它正在評估維拉布替尼與嵌合抗原受體T細胞療法和VRX-510在各種腫瘤學適應症中的開發和合作機會。該公司於2021年2月25日在Viracta治療公司的前身為Sunesis製藥公司。維亞克塔治療公司成立於1998年，總部設在加利福尼亞州的加的夫。
ESSA Pharma Company Profile (Get Rating)
Essa製藥公司簡介(獲取評級)
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Essa Pharma Inc.是一家臨牀階段製藥公司，專注於開發治療前列腺癌的新型專利療法。它開發了EPI-7386，這是一種口服候選藥物，正在進行I期臨牀研究，用於治療轉移性去勢抵抗前列腺癌患者。該公司與Caris Life Science，Inc.，Bayer Consumer Care AG，Janssen Research&Development，LLC和Astellas Pharma Inc.簽訂了合作協議。Essa Pharma Inc.成立於2009年，總部設在加拿大温哥華。
Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《維拉克塔治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Viracta Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
